Assessing CONMED (CNMD) Valuation As Revenue Growth Trails Sector And A 1.3% Decline Is Forecast

Simply Wall St.

Mar 15

AdvertisementEvent driven rethink of CONMED (CNMD) Recent commentary that CONMED (CNMD) could see a 1.3% revenue decline over the next year, after sales growth already lagged the broader healthcare ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2619176800"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2619176800\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2619176800?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","is_english":true,"pubTime":"2026-03-15 06:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619176800","market":"sg","top_or_hot":-1,"title":"Assessing CONMED (CNMD) Valuation As Revenue Growth Trails Sector And A 1.3% Decline Is Forecast","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementEvent driven rethink of CONMED (CNMD) Recent commentary that CONMED (CNMD) could see a 1.3% revenue decline over the next year, after sales growth already lagged the broader healthcare ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-cnmd/conmed/news/assessing-conmed-cnmd-valuation-as-revenue-growth-trails-sec\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing CONMED (CNMD) Valuation As Revenue Growth Trails Sector And A 1.3% Decline Is Forecast</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing CONMED (CNMD) Valuation As Revenue Growth Trails Sector And A 1.3% Decline Is Forecast\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-15 06:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-cnmd/conmed/news/assessing-conmed-cnmd-valuation-as-revenue-growth-trails-sec><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementEvent driven rethink of CONMED (CNMD) Recent commentary that CONMED (CNMD) could see a 1.3% revenue decline over the next year, after sales growth already lagged the broader healthcare ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-cnmd/conmed/news/assessing-conmed-cnmd-valuation-as-revenue-growth-trails-sec\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CNMD","symbol_name":"CONMED Corporation","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-cnmd/conmed/news/assessing-conmed-cnmd-valuation-as-revenue-growth-trails-sec","article_id":"2619176800","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-cnmd/conmed/news/assessing-conmed-cnmd-valuation-as-revenue-growth-trails-sec","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2619176800","pubTimestamp":1773526679,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Event driven rethink of CONMED (CNMD)\nRecent commentary that CONMED (CNMD) could see a 1.3% revenue decline over the next year, after sales growth already lagged the broader healthcare sector, has sharpened investor focus on the company's demand outlook.\nSee our latest analysis for CONMED.\nAt a share price of US$37.28, CONMED has seen pressure build over time, with a 30 day share price return of an 11.93% decline and a 1 year total shareholder return of a 36.16% loss. This points to fading...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CNMD":"CONMED Corporation"},"translate_title":"评估CONMED(CNMD)的估值，因为收入增长落后于行业，预计下降1.3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CNMD":1.5},"content_text":"AdvertisementEvent driven rethink of CONMED (CNMD) Recent commentary that CONMED (CNMD) could see a 1.3% revenue decline over the next year, after sales growth already lagged the broader healthcare sector, has sharpened investor focus on the company's demand outlook. See our latest analysis for CONMED. At a share price of US$37.28, CONMED has seen pressure build over time, with a 30 day share price return of an 11.93% decline and a 1 year total shareholder return of a 36.16% loss. This points to fading momentum as investors reassess the outlook following softer revenue expectations. If this revenue concern has you reassessing your watchlist, it could be a good moment to broaden your search and check out 18 top founder-led companies as potential alternatives. With the share price down sharply over 1 and 3 years yet trading at an implied discount to some analyst targets and intrinsic estimates, you have to ask yourself: is this a reset opportunity, or is weak future growth already priced in? Most Popular Narrative: 23% Undervalued With CONMED closing at $37.28 versus a widely followed fair value estimate of $48.40, the core narrative treats the current price as a material discount that hinges on execution in its core surgical focus areas.  Ongoing operational improvements, particularly in resolving supply chain constraints and optimizing procurement and production, are set to unlock capacity, enable share recovery in orthopedics, and generate material cost efficiencies, likely yielding margin expansion and stronger earnings growth as these initiatives take effect.  Read the complete narrative. Curious what kind of revenue run rate and margin profile sit behind that $48.40 figure, and how a lower future earnings multiple still supports it? The full narrative lays out the revenue growth glide path, margin rebuild and discount rate that need to hold for this gap to close. Result: Fair Value of $48.40 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, you still need to weigh the risk that supply chain issues or hospital capital spending pressure could limit revenue progress and keep margins from improving as modeled. Find out about the key risks to this CONMED narrative. Next Steps With that mix of concern and potential on the table, are you comfortable relying on one headline view, or do you want to move quickly and test the assumptions yourself by weighing 4 key rewards and 3 important warning signs? Looking for more investment ideas? If this story has you rethinking where you put fresh capital, do not stop at one stock. Use the Simply Wall St screener today and see what you might be missing.  Spot fresh value ideas early by scanning our screener containing 26 high quality undiscovered gems that combine quality fundamentals with low market attention. Strengthen your income stream by reviewing a hand picked list of 14 dividend fortresses that could help anchor a yield focused portfolio. Sleep a little easier by comparing companies in our 68 resilient stocks with low risk scores that score well on balance sheet strength and risk checks.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}